Home  >  News
Eppen_Tubes_Nov2022
you can get e-magazine links on WhatsApp. Click here
Biotechnology + Font Resize -

Bavarian Nordic awarded 10-year contract amendment valued up to USD 434 mn for supply of smallpox & monkeypox vaccine to Canada

Copenhagen, Denmark
Wednesday, September 21, 2022, 12:00 Hrs  [IST]

Bavarian Nordic A/S announced a revised contract with the Public Health Agency of Canada (PHAC) to supply doses of Imvamune smallpox vaccine at a value of approximately USD 234 million in addition to USD 180 million in contract options. This extends the USD 56 million contract awarded in June 2022 to a total value of up to USD 470 million. Furthermore, a new multi-year contract has been signed with Canada’s Department of National Defence (DND) at a value of USD 2 million, in addition to USD 18 million in contract options.

Through these agreements, the majority of the firm order supply will be delivered in 2023 with the option to procure additional doses annually until 2032 for a total additional value of up to USD 198 million.

Paul Chaplin, president & chief executive officer of Bavarian Nordic, said: “With foresight and prioritization, Canada has shown the way to building a robust preparedness for its population. As a trusted supplier of smallpox vaccines to the Canadian authorities since 2008, we are pleased to extend and expand our collaboration for the next decade, thus helping to maintain the readiness for Canada to respond quickly to emergencies, such as the current monkeypox outbreak.”

MVA-BN or Modified Vaccinia Ankara-Bavarian Nordic (marketed as Imvanex in Europe, Jynneos in the US and Imvamune in Canada) is a non-replicating smallpox vaccine developed in collaboration with the US government to ensure supply of a smallpox vaccine for the entire population, including immunocompromised individuals who are not recommended vaccination with traditional replicating smallpox vaccines. In addition to smallpox, the US Food and Drug Administration, Health Canada and the European Commission have also approved the vaccine for use against monkeypox as the only vaccine having obtained this to-date.

Bavarian Nordic has ongoing supply contracts with USA and Canada and has delivered the vaccine to a number of undisclosed countries globally as part of their national biological preparedness. In recent years, smaller quantities of the vaccine have been supplied in response to sporadic cases of monkeypox. During the ongoing 2022 outbreak of monkeypox, Bavarian Nordic has worked with several governments to fulfil the immediate demand for the vaccine through a number of supply agreements and is working to secure manufacturing of vaccines to fulfil the demand in the medium- to long term.

Bavarian Nordic is a fully integrated vaccines company focused on the development, manufacturing and commercialization of life-saving vaccines.

 

*POST YOUR COMMENT
Comments
* Name :     
* Email :    
  Website :  
   
     
 
Apollo Clinical Research
truking"
 
 
Copyright © 2016 Saffron Media Pvt. Ltd |